"Inflammation" covers a lot of ground: an autoimmune flare, a slow-healing wound, a joint that will not calm down, a gut that reacts to everything. Five peptides get sold in the Philippines with an anti-inflammatory story attached, and they sit at very different points on the evidence scale. One is a decades-old approved medicine used for something adjacent to general inflammation. Two have completed real human trials for narrow indications. Two have never been given to a person in a published study. This guide ranks them by what was actually tested, not by which one shows up most in a supplier's product description.
Summary
| Compound | Best evidence | Stage |
|---|---|---|
| Thymosin alpha-1 | Approved medicine (Zadaxin) in 35+ countries, immune modulator for hepatitis B and C | Approved abroad for a specific indication; not an inflammation drug by label |
| LL-37 | Two randomized, placebo-controlled human trials, topical, for venous leg ulcers | Investigational topical formulation; not approved |
| ARA-290 | Phase 2 human trials for neuropathy in sarcoidosis and type 2 diabetes | Small, company-linked phase 2 trials; not approved |
| BPC-157 Stocked locally | Extensive rat and mouse gut and tissue studies; one uncontrolled human case series | Animal data plus a single case series with no control group |
| KPV | Mouse and rat colitis models, cell studies of the uptake mechanism | Cell and animal only; no published human trial |
Thymosin alpha-1: an approved drug, but not for "inflammation" as a label
Thymosin alpha-1 is one of the few compounds discussed anywhere on this site that is an actual registered medicine abroad. Sold as Zadaxin, chemical name thymalfasin, it has been used in more than 35 countries for chronic hepatitis B and C, working through T-cell modulation and altered cytokine signalling rather than a single anti-inflammatory receptor. A 2026 Cochrane review re-examined the hepatitis B trial evidence pooled from 1991 to 2018, which is the kind of scrutiny most peptides on this page have never received in any form. None of that makes it an approved treatment for inflammation broadly: its regulatory approval is specific to viral hepatitis, and it has never been approved by the US FDA. See the full trial history on the thymosin alpha-1 page.
LL-37: real human trials, but for a wound, not general inflammation
LL-37 is the human body's own cathelicidin peptide, made naturally by neutrophils and skin cells. Its published human trials are specific: a 2014 randomized, placebo-controlled trial and a larger 148-patient phase IIb trial both tested a topical LL-37 gel added to compression therapy in patients with hard-to-heal venous leg ulcers. Both showed a benefit that earned the formulation continued clinical development, but neither is a general inflammation trial, and no injectable or oral human trial of LL-37 has been published.
The mechanism cuts both ways. LL-37 fights bacteria directly and recruits immune cells to a wound, which is the basis for the ulcer trials. In psoriasis research, the same peptide binding self-DNA and self-RNA released from damaged skin cells is described as a driver of the overactive immune response seen in that disease. That is a mechanism finding used to explain part of psoriasis, not a therapeutic claim about a manufactured LL-37 product. Full detail is on the LL-37 page.
ARA-290: phase 2 trials, narrow condition, company-linked data
ARA-290 (cibinetide) is engineered from erythropoietin to keep its tissue-protective, anti-inflammatory signalling without the blood-cell-stimulating effect of EPO. Its published human work sits in phase 2: trials in sarcoidosis-associated and type 2 diabetes-associated small fibre neuropathy reported improvements in neuropathic symptoms and, in one trial, corneal nerve fibre density measured by confocal microscopy. These are small studies, and the developing company, Araim Pharmaceuticals, is connected to several of the authors, which is typical for early peptide development but a reason to wait for the finding to be replicated by an outside research group. No phase 3 trial exists and no regulator has approved it. More on the ARA-290 page.
BPC-157: rats, mice, and one case series
BPC-157 has the largest research literature of the five, almost all of it in rats and mice: gut ulcers, surgical bowel connections, colitis, and tendon and ligament injury. The one published human report is a 2021 case series of intra-articular BPC-157 injections for knee pain, printed in a complementary-medicine journal. A case series has no comparison group, so it cannot show the injections caused any change; it only documents that they were given. The US FDA nominated BPC-157 to its compounding safety-risk list in 2023 and withdrew that nomination in April 2026, a procedural change, not an approval. Full trial list on the BPC-157 page.
KPV: cell and mouse work only
KPV is the smallest fragment on this list, three amino acids cut from alpha-MSH, and it has no published human data at all. Researchers led by Kannengiesser and by Dalmasso showed anti-inflammatory activity in mouse colitis models and traced a specific uptake route through the PepT1 transporter into intestinal cells, where KPV appears to dampen the NF-kB signalling that drives gut inflammation. More recent papers, including a 2017 nanoparticle-delivery study and a 2021 hydrogel study, are mostly about engineering ways to deliver the peptide orally, still in mice and rats. That is a real and reasonably consistent animal literature, but it has not moved into a human trial. See the KPV page.
Why the field looks stronger than the human data supports
Anti-inflammatory claims travel faster online than the trials that would support them. Of the five compounds here, only two, LL-37 and ARA-290, have any randomized, controlled human data, and both are for narrow, specific conditions rather than inflammation in general. Thymosin alpha-1's approval is real but sits outside a general anti-inflammatory indication. BPC-157 and KPV are supported entirely by animal and cell work, however extensive. None of this rules out that these peptides do something in people; it means nobody has published the trial that would show it.
Safety notes
Thymosin alpha-1 has a multi-decade safety record in the countries where Zadaxin is registered, generally described as well tolerated with injection-site reactions as the most common complaint. The LL-37 ulcer trials had structured safety monitoring built in as part of the clinical trial design. ARA-290's phase 2 trials described it as generally well tolerated, consistent with its design goal of avoiding EPO's red-blood-cell risks. BPC-157 and KPV have no controlled human safety data of any kind; what exists is animal tolerability, which does not establish what an injected research-market vial does in a person. See side effect management for general injection-site and monitoring guidance.
Status in the Philippines
None of the five is registered with FDA Philippines. Thymosin alpha-1's registration status specifically could not be confirmed because the agency's online verification portal requires an interactive search this research could not complete. None is a scheduled controlled substance under RA 9165. Where they are available locally, LL-37, ARA-290, BPC-157 and KPV are sold only through research-chemical channels, not as medicines, and Zadaxin brand thymosin alpha-1 would need pharmacy verification rather than research-supplier sourcing. Anyone dealing with a chronic inflammatory condition is better served starting with a licensed Philippine physician, since treatable underlying causes are common and none of these compounds is a substitute for a diagnosis.
